January 18, 2012
FOR IMMEDIATE RELEASE
WaferGen Contacts
510-651-4450
Don Huffman, CFO
don.huffman@wafergen.com
Media: Joyce Strand
joyce.strand@wafergen.com
Fremont, Calif., January 18, 2012 - WaferGen Biosystems,
Inc. (OTCBB:WGBS), an emerging genomic analysis company,
today announced that Scott R. Davidson and Joseph F. Pesce,
CPA, have joined the company's Board of Directors.
Scott R. Davidson currently serves as Managing Director at
Great Point Partners, Greenwich, CT. As part of his
investment functions, he leads Great Point Partners'
medical devices and diagnostics investing efforts. Prior to
joining Great Point, he served in various capacities at
Piper Jaffray & Co.; Bear, Stearns & Co.; Robertson
Stephens & Co.; and Canaan Partners. He holds an A.B. from
Harvard College and an M.B.A. from Stanford Graduate School
of Business where he was an Arjay Miller Scholar.
Joseph F. Pesce has been a Managing Director and Operating
Partner of Great Point Partners, LLC since January 1, 2011.
Previously, he was the Chief Financial Officer and
Treasurer of Thomas H. Lee Partners, whom he joined in
2001, and where he was promoted to Managing Director and
Chief of Operations in 2006. Most recently, he has served
as that firm's Chief Risk Officer. Prior to that, Mr. Pesce
spent over 25 years in senior financial positions in high
technology, healthcare and consulting services companies.
Mr. Pesce received an A.B. in Mathematics with honors from
Boston College and an M.B.A. from the Wharton School of the
University of Pennsylvania. He is a Certified Public
Accountant and a member of The American Institute of
Certified Public Accountants, the Massachusetts Society of
Certified Public Accountants and Financial Executives
International.
About WaferGen and the SmartChip Real-Time PCR System
WaferGen Biosystems, Inc., an emerging genomic analysis
company in the early stage of commercialization, offers the
transformative SmartChip Real-Time PCR System-a
next-generation Real-Time PCR System for profiling and
validation of gene expression patterns (biomarkers) on a
single platform. The SmartChip System provides a range of
high-throughput capabilities including microRNA and mRNA
gene expression profiling and Single Nucleotide
Polymorphism (SNP) genotyping. WaferGen also offers
Quick-Turnaround SmartChip Custom (User-Defined) Panels to
enable validation studies of specific genes of interest
through customization of high-throughput, real-time PCR
SmartChip assay panels-all on a quick-turnaround basis.
In addition, the Company offers an innovative fee-based
service for gene-expression profiling using the SmartChip
System. For additional information, please see
Forward Looking Statements
This press release contains certain "forward-looking
statements". Such statements include statements relating to
the contributions of Scott R. Davidson and Joseph Pesce,
CPA, statements relating to the expected throughput levels
of the SmartChip Real-Time PCR System, and other statements
relating to future events are not historical facts,
including statements which may be preceded by the words
"intends," "may," "will," "plans," "expects,"
"anticipates," "projects," "predicts," "estimates," "aims,"
"believes," "hopes," "potential" or similar words.
Forward-looking statements are not guarantees of future
performance, are based on certain assumptions and are
subject to various known and unknown risks and
uncertainties, many of which are beyond the control of the
company. Actual results may differ materially from the
expectations contained in the forward-looking statements.
Factors that may cause such differences include the risks
that: (i) the company may be unsuccessful in commercially
developing its products or in achieving market acceptance
of new and relatively unproven technologies; (ii) the
company may need to raise additional capital to meet its
business requirements in the future and the company may not
be able to do so on reasonable terms or at all; (iii) the
company's proprietary intellectual property rights may not
adequately protect its products and technologies; and (iv)
the company expects intense competition in its target
markets, including from companies that have much greater
resources than the company, and there can be no assurance
that the company will be able to compete effectively. More
detailed information about the company and the risk factors
that may affect the realization of forward-looking
statements is set forth in the company's filings with the
Securities and Exchange Commission, including the company's
Annual Report on Form 10-K for the year ended December 31,
2010 and the company's most recent Quarterly Report on Form
10-Q for the period ended September 30, 2011. Security
holders are urged to read these documents free of charge on
the SEC's web site at www.sec.gov. The company does not
undertake to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
distribué par | Ce noodl a été diffusé par WaferGen Biosystems Inc. et initialement mise en ligne sur le site http://www.wafergen.com. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-27 01:54:45 AM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité. |